113. Muscular dystrophy Clinical trials / Disease details


Clinical trials : 622 Drugs : 485 - (DrugBank : 99) / Drug target genes : 59 - Drug target pathways : 168

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-024659-10-DK
(EUCTR)
03/08/201121/06/2011Can certain muscle wasting diseases be improved with sildenafil?Can stimulation of the nNOS system in muscle disease with nNOS insufficiency improve heart and skeletal muscle function and cognition? Muscular dystrophy with nNOS insufficiency
MedDRA version: 14.0;Level: LLT;Classification code 10028301;Term: Muscle disorder NOS;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Trade Name: Revatio
Product Name: Sildenafil
Product Code: EMEA/H/C/000638
RigshospitaletNULLNot RecruitingFemale: no
Male: yes
Denmark
2NCT01168908
(ClinicalTrials.gov)
September 201022/7/2010Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular DystrophyPhase 2 Clinical Trial of Sildenafil for Cardiac Dysfunction in Duchenne Muscular Dystrophy and Becker Muscular DystrophyDuchenne Muscular Dystrophy;Becker Muscular DystrophyDrug: SildenafilHugo W. Moser Research Institute at Kennedy Krieger, Inc.Johns Hopkins UniversityTerminated18 Years50 YearsMale20Phase 2United States